Dicerna Pharmaceuticals Total Current Liabilities

Dicerna Pharmaceuticals (DRNA) currently reports a total current liabilities of $240M as of September 2021. That compares with $240M in the prior-year period — down 0.2% year over year. Use the charts on this page to explore Dicerna Pharmaceuticals's total current liabilities history and peer comparisons.

Dicerna Pharmaceuticals's total current liabilities decreased from $240M to $240M — a 0.2% year-over-year decrease (period ending September 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Dicerna Pharmaceuticals reported $240M in total current liabilities as of September 2021. That compares with $240M in the prior-year period — down 0.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $240M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Dicerna Pharmaceuticals, and consider following DRNA for alerts when major investors trade the stock.

Dicerna Pharmaceuticals is classified in the Healthcare sector. On total current liabilities, it currently shows $240M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DRNA with unrelated industries.